Displaying 13 - 21 of 21
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Immune-Mediated and Cholestatic Diseases
1

Albireo: Challenges in the Management of Patients with Cholestatic Liver Diseases - Digital ILC 2020

View
Displaying 13 - 21 of 21